Statement: the primary trial recorded 2 more total adverse events than the secondary trial
Primary_evidence: Adverse Events 1:   Total: 5/14 (35.71%)   Ileus 1/14 (7.14%)   General disorders and administration site conditions - Other, disease progression 2/14 (14.29%)   Infections and infestations - Other, pneumonia 1/14 (7.14%)   Acute kidney injury 1/14 (7.14%)
Secondary_evidence: Adverse Events 1:   Total: 3/9 (33.33%)   Fatigue * 1/9 (11.11%)   Non-cardiac chest pain * 1/9 (11.11%)   Sepsis * 1/9 (11.11%)   Urinary tract infection * 1/9 (11.11%)   Syncope * 1/9 (11.11%)   Anxiety * 1/9 (11.11%)   Thromboembolic event * 1/9 (11.11%)